{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T06:54:11Z","timestamp":1788245651599,"version":"build-2803163510"},"reference-count":22,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2011,3,1]],"date-time":"2011-03-01T00:00:00Z","timestamp":1298937600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Transplantation Proceedings"],"published-print":{"date-parts":[[2011,3]]},"DOI":"10.1016\/j.transproceed.2011.01.075","type":"journal-article","created":{"date-parts":[[2011,4,19]],"date-time":"2011-04-19T01:33:29Z","timestamp":1303176809000},"page":"453-457","source":"Crossref","is-referenced-by-count":11,"title":["Comparison of Basiliximab and Daclizumab With Triple Immunosuppression in Renal Transplantation"],"prefix":"10.1016","volume":"43","author":[{"given":"S.","family":"Aktas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Colak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Baskin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Sevmis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Ozdemir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Moray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Karakayali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Haberal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.transproceed.2011.01.075_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0966-3274(98)80029-4","article-title":"Risk factors for chronic rejection\u2014a clinical perspective","volume":"6","author":"Matas","year":"1998","journal-title":"Transpl Immunol"},{"key":"10.1016\/j.transproceed.2011.01.075_bib2","doi-asserted-by":"crossref","first-page":"655","DOI":"10.2165\/00063030-200115100-00003","article-title":"Role of anti-interleukin-2 receptor antibodies in kidney transplantation","volume":"15","author":"Cibrik","year":"2001","journal-title":"BioDrugs"},{"key":"10.1016\/j.transproceed.2011.01.075_bib3","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1034\/j.1399-0012.2003.00066.x","article-title":"The use of daclizumab as induction therapy in combination with tacrolimus and mycophenolate mofetil in recipients with previous transplants","volume":"17","author":"Ciancio","year":"2003","journal-title":"Clin Transplant"},{"key":"10.1016\/j.transproceed.2011.01.075_bib4","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1111\/j.1600-6143.2007.01860.x","article-title":"Efficacy of anti-IL-2 receptor antibodies compared to no induction and to antilymphocyte antibodies in renal transplantation","volume":"7","author":"Patlolla","year":"2007","journal-title":"Am J Transplant"},{"key":"10.1016\/j.transproceed.2011.01.075_bib5","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1097\/01.tp.0000219817.18049.36","article-title":"Disassociation between risk of graft loss and risk of non-Hodgkin lymphoma with induction agents in renal transplant recipients","volume":"81","author":"Opelz","year":"2006","journal-title":"Transplantation"},{"key":"10.1016\/j.transproceed.2011.01.075_bib6","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1097\/00007890-199712270-00016","article-title":"Comparative study of cytomegalovirus (CMV) antigenemia assay, polymerase chain reaction, serology, and shell vial assay in the early diagnosis and monitoring of CMV infection after renal transplantation","volume":"64","author":"Tanabe","year":"1997","journal-title":"Transplantation"},{"key":"10.1016\/j.transproceed.2011.01.075_bib7","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.transproceed.2007.11.004","article-title":"Renal scintigraphy findings in allograft recipients with increased resistance index on Doppler sonography","volume":"40","author":"Kocaba\u015f","year":"2008","journal-title":"Transplant Proc"},{"key":"10.1016\/j.transproceed.2011.01.075_bib8","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1111\/j.1600-6143.2008.02159.x","article-title":"Banff 07 classification of renal allograft pathology: updates and future directions","volume":"8","author":"Solez","year":"2008","journal-title":"Am J Transplant"},{"key":"10.1016\/j.transproceed.2011.01.075_bib9","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1034\/j.1600-6143.2002.020109.x","article-title":"Immunoprophylaxis with basiliximab compared with antithymocyte globulin in renal transplant patients receiving MMF-containing triple therapy","volume":"2","author":"Lebranchu","year":"2002","journal-title":"Am J Transplant"},{"key":"10.1016\/j.transproceed.2011.01.075_bib10","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1034\/j.1600-6143.2002.020205.x","article-title":"Reduction in acute rejections decreases chronic rejection graft failure in children: a report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS)","volume":"2","author":"Tejani","year":"2002","journal-title":"Am J Transplant"},{"key":"10.1016\/j.transproceed.2011.01.075_bib11","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1034\/j.1399-0012.2000.140511.x","article-title":"The effect of daclizumab in a high-risk renal transplant population","volume":"14","author":"Meier-Kriesche","year":"2000","journal-title":"Clin Transplant"},{"key":"10.1016\/j.transproceed.2011.01.075_bib12","doi-asserted-by":"crossref","first-page":"2767","DOI":"10.1016\/S0041-1345(01)02184-4","article-title":"Induction immunosuppression with interleukin-2 receptor antibodies (basiliximab and daclizumab) in renal transplant recipients","volume":"33","author":"Nair","year":"2001","journal-title":"Transplant Proc."},{"key":"10.1016\/j.transproceed.2011.01.075_bib13","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1097\/00007890-200011150-00015","article-title":"Double-blind comparison of two corticosteroid regimens plus mycophenolate mofetil and cyclosporine for prevention of acute renal allograft rejection","volume":"70","author":"Vanrenterghem","year":"2000","journal-title":"Transplantation"},{"key":"10.1016\/j.transproceed.2011.01.075_bib14","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1097\/01.TP.0000109643.32659.C4","article-title":"Interleukin 2 receptor antagonists for renal transplant recipients: a meta-analysis of randomized trials","volume":"77","author":"Webster","year":"2004","journal-title":"Transplantation"},{"key":"10.1016\/j.transproceed.2011.01.075_bib15","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1034\/j.1600-6143.2002.20612.x","article-title":"Limited dose monoclonal IL-2R antibody induction protocol after primary kidney transplantation","volume":"2","author":"Ahsan","year":"2002","journal-title":"Am J Transplant"},{"key":"10.1016\/j.transproceed.2011.01.075_bib16","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1111\/j.1600-6143.2006.01645.x","article-title":"Cyclosporine sparing with mycophenolate mofetil, daclizumab and corticosteroids in renal allograft recipients: the CAESAR Study","volume":"7","author":"Ekberg","year":"2007","journal-title":"Am J Transplant"},{"key":"10.1016\/j.transproceed.2011.01.075_bib17","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1034\/j.1399-0012.2003.00038.x","article-title":"The use of an anti-CD25 monoclonal antibody and mycophenolate mofetil enables the use of a low-dose tacrolimus and early withdrawal of steroids in renal transplant recipients","volume":"17","author":"Kuypers","year":"2003","journal-title":"Clin Transplant"},{"key":"10.1016\/j.transproceed.2011.01.075_bib18","first-page":"51","article-title":"Basiliximab induction therapy in kidney transplantation: benefits for long term allograft function after 10 years?","volume":"3","author":"Koch","year":"2009","journal-title":"Biologics"},{"key":"10.1016\/j.transproceed.2011.01.075_bib19","first-page":"172","article-title":"Steroid-resistant acute rejections after liver transplant","volume":"8","author":"Aydogan","year":"2010","journal-title":"Exp Clin Transplant"},{"key":"10.1016\/j.transproceed.2011.01.075_bib20","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/S0161-5890(03)00072-5","article-title":"Comparison of daclizumab, an interleukin 2 receptor antibody, to anti-thymocyte globulin-Fresenius induction therapy in kidney transplantation","volume":"39","author":"Abou-Jaoude","year":"2003","journal-title":"Mol Immunol"},{"key":"10.1016\/j.transproceed.2011.01.075_bib21","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1097\/01.TP.0000100826.58738.2B","article-title":"Association of the type of induction immunosuppression with posttransplant lymphoproliferative disorder, graft survival, and patient survival after primary kidney transplantation","volume":"76","author":"Cherikh","year":"2003","journal-title":"Transplantation"},{"key":"10.1016\/j.transproceed.2011.01.075_bib22","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1097\/00007890-199907270-00028","article-title":"Cytomegalovirus infections after treatment with daclizumab, an anti IL-2 receptor antibody, for prevention of renal allograft rejection","volume":"68","author":"Hengster","year":"1999","journal-title":"Transplantation"}],"container-title":["Transplantation Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004113451100159X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004113451100159X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,3]],"date-time":"2018-12-03T06:25:26Z","timestamp":1543818326000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S004113451100159X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,3]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,3]]}},"alternative-id":["S004113451100159X"],"URL":"https:\/\/doi.org\/10.1016\/j.transproceed.2011.01.075","relation":{},"ISSN":["0041-1345"],"issn-type":[{"value":"0041-1345","type":"print"}],"subject":[],"published":{"date-parts":[[2011,3]]}}}